SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

[ X ]       QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
            EXCHANGE ACT OF 1934.

            For the quarterly period ended September 30, 2002.

            OR

[   ]       TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
            EXCHANGE ACT OF 1934.

            For the transition period from             to
                                           -----------    -----------

            Commission file number

                          Bio-Medical Automation, Inc.
                          ----------------------------
       (Exact name of small business issuer as specified in its charter.)

         Colorado                     0-16335               84-0922701
----------------------------      ----------------         -------------
(State or other jurisdiction      (Commission File         (IRS Employer
     of incorporation)                 Number)          Identification No.)


                 10 South Street, Suite. 202, Ridgefield, CT 06877

                                 (203) 894-9755
                                 --------------
                           (Issuer's telephone number,
                              including area code)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.  Yes  X   No
                                                               ---     ---

As of November 11, 2002 the Registrant had outstanding 813,028 shares of common
stock, par value $.10

Transitional Small Business Disclosure Format (check one):
Yes      No  X
    ---     ---

<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                                   FORM 10-QSB
                               SEPTEMBER 30, 2002


                                                                            Page
Part I  -  Financial Information

Item 1. Financial Statements

        Balance Sheets as of December 31, 2001
             and September 30, 2002 (unaudited)                               3

        Statements of Operations for the Nine Months Ended
             September 30, 2001 and 2002 and Cumulative Amounts from
             January 1, 2000 through September 30, 2002 (unaudited)           4

        Statements of Operations for the Three Months Ended
             September 30, 2001 and 2002 (unaudited)                          5

        Statements of Cash Flows for the Nine Months Ended September 30, 2001
                  and 2002 and Cumulative Amounts from
             January 1, 2000 through September 30, 2002 (unaudited)           6

        Notes to Financial Statements                                         7

Item 2. Management Discussion and Analysis
             and Plan of Operations                                           8

Part II - Other Information                                                  10

Item 5. Other Information                                                    10

Item 6. Exhibits & Reports on Form 8-K                                       11

Signatures                                                                   11


<PAGE>

                         Part I - Financial Information

Item 1.     Financial Statements

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                      December 31,   September 30,
                                                                          2001           2002
                                                                                      (Unaudited)
<S>                                                                   <C>             <C>
                                              ASSETS
CURRENT ASSETS
    Cash                                                              $   341,611     $   323,519
    Interest receivable - officer                                                           4,512
                                                                      -----------     -----------
                                                                                            2,262

        Total Current Assets                                              343,873         328,031
                                                                      -----------     -----------

                                                                      $   343,873     $   328,031
                                                                      ===========     ===========


                             LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable and accrued expenses                             $     7,679     $    34,369
                                                                      -----------     -----------

        Total Current Liabilities                                           7,679          34,369
                                                                      -----------     -----------


STOCKHOLDERS' EQUITY
    Preferred Stock, $.10 par value; authorized - 1,000,000 shares
           Issued - none
    Common Stock, $.10 par value; authorized - 5,000,000 shares
           Issued and outstanding - 813,028 shares                         81,303          81,303
    Capital in excess of par value                                      1,464,884       1,595,509
    Note receivable - officer                                             (50,000)        (50,000)
    Stock issued for deferred compensation                                (11,000)             --
    Accumulated (deficit)                                                (947,820)       (947,820)
    (Deficit) accumulated during the development stage                   (201,173)       (385,330)
                                                                      -----------     -----------

                                                                          336,194         293,662
                                                                      -----------     -----------

                                                                      $   343,873     $   328,031
                                                                      ===========     ===========
</TABLE>

                See accompanying notes to financial statements.

                                       3
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                          Cumulative
                                                 Nine Months Ended   Amounts from January 01,
                                                    September 30,          2000 to
                                                 2001          2002   September 30, 2002
<S>                                           <C>           <C>           <C>
REVENUES
      Interest income                         $   6,575     $   5,701     $  19,595
                                              ---------     ---------     ---------

OPERATING EXPENSES
    General and Administrative                   58,714        59,232       255,576
      Compensation expense - stock options           --       130,625       130,625
      Write-off of patent                            --            --        18,724
                                              ---------     ---------     ---------

                                                 58,714       189,857       404,925
                                              ---------     ---------     ---------


NET (LOSS)                                    $ (52,139)    $(184,156)    $(385,330)
                                              =========     =========     =========

NET (LOSS) PER COMMON SHARE
    Basic and Diluted
                                              $   (0.07)    $    (.23)    $    (.46)
                                              =========     =========     =========



WEIGHTED AVERAGE NUMBER OF
    COMMON SHARES OUTSTANDING -
    Basic and Diluted                           767,044       813,028       829,736
                                              =========     =========     =========
</TABLE>





                 See accompanying notes to financial statements.

                                        4
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

                                                        Three Months Ended
                                                           September 30,
                                                        2001          2002
REVENUES

          Interest Income                            $   2,341     $   2,243
                                                     ---------     ---------

OPERATING EXPENSES

         General and administrative                     14,079        21,621
                                                     ---------     ---------


NET (LOSS)                                           $ (11,738)    $ (19,378)
                                                     =========     =========

NET (LOSS) PER COMMON SHARE
          Basic and Diluted                          $   (0.01)    $   (0.02)
                                                     =========     =========


WEIGHTED AVERAGE NUMBER OF COMMON
          SHARES OUTSTANDING
          Basic and Diluted                            795,528       813,028
                                                     =========     =========










                 See accompanying notes to financial statements

                                        5
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                          Cumulative
                                                                 Nine Months Ended   Amounts from January 01,
                                                                   September 30,            2000 to
                                                               2001            2002   September 30, 2002
<S>                                                         <C>            <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITES
         Net (loss)                                         $ (52,139)     $(184,156)     $(385,330)
         Adjustment to reconcile net (loss) to net cash
            (used) by operating activities
            Stock issuance for salary                          36,000         11,000         96,000
            Stock options                                          --        130,625        130,625
            Stock issued for professional services                 --             --         18,200
            Write-off of patent                                    --             --         18,724
         Changes in assets and liabilities
            (Increase) in interest receivable                  (1,512)        (2,250)        (4,512)
            Increase (decrease) in accounts payable and
                  accrued expenses                             (1,099)        18,976
                                                            ---------      ---------      ---------
                                                                                             26,689

        Net Cash (Used) by Operating Activities               (18,750)       (18,092)      (107,317)
                                                            ---------      ---------      ---------

CASH FLOWS FROM INVESTING ACTIVITIES
        Net Cash (Used) in Investing Activities                    --             --             --
                                                            ---------      ---------      ---------

CASH FLOWS FROM FINANCING ACTIVITIES
        Exercise of common stock warrants                          --             --          5,625
                                                            ---------      ---------      ---------

        Net Cash Provided by Financing Activities                  --             --          5,625
                                                            ---------      ---------      ---------

NET (DECREASE) IN CASH                                        (18,750)       (18,092)      (101,692)

CASH, BEGINNING OF PERIODS                                    360,741        341,611        425,211
                                                            ---------      ---------      ---------

CASH, END OF PERIODS                                        $ 341,991      $ 323,519      $ 323,519
                                                            =========      =========      =========
</TABLE>



                See accompanying notes to financial statements.

                                        6
<PAGE>

         The unaudited financial statements included herein were prepared from
the records of the Company in accordance with Generally Accepted Accounting
Principles and reflect all adjustments which are, in the opinion of management,
necessary to provide a fair statement of the results of operations and financial
position for the interim periods. Such financial statements generally conform to
the presentation reflected in the Company's Form 10-KSB filed with the
Securities and Exchange Commission for the year ended December 31, 2001. The
current interim period reported herein should be read in conjunction with the
Company's Form 10-KSB subject to independent audit at the end of the year.

         The results of operations for the nine months ended September 30, 2002
are not necessarily indicative of the results that may be expected for the year
ending December 31, 2002.


NOTE 1. COMMON STOCK

         In 2001, the Company issued 38,400 shares of common stock (valued at $
1.25 per share) to its President for services to be rendered to the Company for
the period of March 25, 2001 through March 24, 2002. Compensation expense to the
Company is recorded as the shares are earned. Unearned shares are shown in the
accompanying 2001 financial statement as stock issued for deferred compensation.

NOTE 2. NOTE RECEIVABLE - OFFICER

         In 2001, the Company loaned the President $50,000 at 6.0%, due March
30, 2003, to exercise warrants to purchase 50,000 shares of the Company's common
stock at $1.00 per share.

NOTE 3. ACCOUNTS PAYABLE

         Accounts payable at September 30, 2002 includes $24,789 due to the
Company's President for salary pursuant to his employment agreement.

NOTE 4. STOCK OPTIONS

         On June 21, 2002, the Board of Directors approved the extension of the
exercise period applicable to 95,000 stock options owned by the President of the
Company. The options were extended to June 24, 2003, at the original exercise
price of $1.125 per share. The Company charged to operations $130,625 as
compensation expense in conjunction with the extension.








                                        7
<PAGE>

Item 2.  Management Discussion and Analysis and Plan of Operations

     The following discussion and analysis provides information which the
Company's management believes to be relevant to an assessment and understanding
of the Company's results of operations and financial condition. This discussion
should be read together with the Company's financial statements and the notes to
financial statements, which are included in this report, as well as the
Company's Annual Report on Form 10-KSB for the year ended December 31, 2001.

     Bio-Medical Automation, Inc. was incorporated as a Colorado corporation on
October 13, 1983 under the name OZO Diversified Automation, Inc. In March 1999,
in connection with the sale of substantially all of the Company's assets the
Company changed its name to Bio-Medical Automation, Inc. ("BMA" or the
"Company").

     The Company has suspended all operations, except for necessary
administrative matters relating to the timely filing of periodic reports as
required by the Securities Exchange Act of 1934. Accordingly, during the three
months ended September 30, 2002 and the year ended December 31, 2001, the
Company has earned no revenues from operations.

     The Company's management is seeking to arrange for a merger, acquisition,
business combination or other arrangement by and between the Company and a
viable operating entity. The Company has not identified a viable operating
entity for a merger, acquisition, business combination or other arrangement, and
there can be no assurance that the Company will ever successfully arrange for a
merger, acquisition, business combination or other arrangement by and between
the Company and a viable operating entity.

     The Company anticipates that the selection of a business opportunity will
be a complex process and will involve a number of risks, because potentially
available business opportunities may occur in many different industries and may
be in various stages of development. Due in part to depressed economic
conditions in a number of geographic areas, rapid technological advances being
made in some industries and shortages of available capital, management believes
that there are numerous firms seeking either the limited additional capital
which the Company will have or the benefits of a publicly traded corporation, or
both. The perceived benefits of a publicly traded corporation may include
facilitating or improving the terms upon which additional equity financing may
be sought, providing liquidity for principal shareholders, creating a means for
providing incentive stock options or similar benefits to key employees,
providing liquidity for all shareholders and other factors.

     In some cases, management of the Company will have the authority to effect
acquisitions without submitting the proposal to the shareholders for their
consideration. In some instances, however, the proposed participation in a
business opportunity may be submitted to the shareholders for their
consideration, either voluntarily by the Board of Directors to seek the
shareholders' advice and consent, or because of a requirement of state law to do
so.

     In seeking to arrange a merger, acquisition, business combination or other
arrangement by and between the Company and a viable operating entity,
management's objective will be to obtain long-term capital appreciation for the
Company's shareholders. There can be no assurance that the Company will be able
to complete any merger, acquisition, business combination or other arrangement
by and between the Company and a viable operating entity.

                                        8
<PAGE>

     The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that the Company will be able
to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there is no assurance that the Company will be able to
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.

The Company Receives a U.S. Patent
----------------------------------

     Following the sale of substantially all of the Company's assets in 1999,
the Company devoted its efforts to the development of a prototype micro-robotic
device (the "micro-robotic device") to manipulate organic tissues on an
extremely small scale for microdissection. The Company filed a patent
application in February 1998, to protect certain features of the system and
method of the micro-robotic device. However, due to the inability of the Company
to complete the micro-robotic device, the Company determined that it would cease
development of the micro-robotic device and, as of June 30, 2000, the
capitalized costs related to the patent underlying the micro-robotic device have
been written off by the Company.

     On March 19, 2002, the Company was awarded United States Patent No. US
6,358,749 B1 for the "Automated System for Chromosome Microdissection and
Medthod of Using Same" (the "Patent").

     The Patent covers an automated system and method for microdissection of a
sample such as chromosomes or other biological material, and in particular, it
relates to a robotic assisted microdissection system and method that
significantly reduces the time and skill needed for cellular and sub-cellular
dissections. Microdissection is defined as dissection under the microscope;
specifically: dissection of cells and tissues by means of fine needles that are
precisely manipulated by levers. The system and method covered by the Patent
attempts to provide reliability and ease of operation thereby making
microdissection widely available to laboratories. While the Company has never
derived any revenues from the micro-robotic device, the Company plans to attempt
to license or sell the technology covered by the Patent. There can be no
assurances that the Company will be able to successfully market the technology
covered by the Patent or that the Company will ever derive any revenues from the
Patent or the technology covered by the Patent.

Results of Operations
---------------------

     For the three month periods ended September 2002 and 2001, the Company has
not earned any revenues, except for interest income of $2,243 and $2,341,
respectively. For the same three month periods the Company incurred expenses of
$21,621 and 14,079, respectively. For the three month periods ended September
2002 and 2001, the Company sustained a net loss equal to $19,378 and 11,738,
respectively. For the nine month periods ended September 2002 and 2001, the
Company has not earned any revenues, except for interest income of $5,701 and
$6,575, respectively. For the same nine month periods the Company incurred
expenses of $189,857 and $58,714, respectively. For the nine month periods ended
September 2002 and 2001, the Company sustained a net loss equal to $184,156 and
$52,139, respectively. For the nine month period ended September 30, 2002
expenses increased by $131,143 as compared to the nine month period ended
September 30, 2001, primarily due to the extension of the exercise period of
certain stock options held by the president of the Company. Excluding the
extension of the exercise period of certain stock options, expenditures of the
Company were and have been directed to maintaining the Company's status as a
public company, including (without limitation) filing reports with the
Securities and Exchange Commission.


                                        9
<PAGE>

Liquidity and Capital Resources
-------------------------------

     During three months ended September 30, 2002, the Company satisfied its
working capital needs from cash on hand at the beginning of the quarter and cash
generated from interest income during the quarter. As of September 30, 2002, the
Company had on hand cash in the amount of $323,519.

     The Company's future financial condition will be subject to its ability to
arrange for a merger, acquisition or a business combination with an operating
business on favorable terms that will result in profitability. There can be no
assurance that the Company will be able to do so or, if it is able to do so,
that the transaction will be on favorable terms not resulting in an unreasonable
amount of dilution to the Company's existing shareholders.

     The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that the Company will be able
to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there is no assurance that the Company will be able to
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.

     Except for historical information contained herein, the statements in this
report are forward-looking statements that are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You can
identify these forward-looking statements when you see words such as "expect,"
"anticipate," "estimate," "may," "believe," and other similar expressions. These
statements are not guarantees of future performance and are subject to certain
risks, uncertainties and assumptions that are difficult to predict. Actual
results could differ materially from those projected in the forward-looking
statements. Forward-looking statements involve known and unknown risks and
uncertainties, which may cause the Company's actual results in future periods to
differ materially, from forecasted results. These and other risks are described
elsewhere herein and in the Company's other filings with the Securities and
Exchange Commission, namely the Company's Form 10-KSB for the year ended
December 31, 2001.


                           PART II - OTHER INFORMATION


Item 5.  Other Information

Disclosure Controls and Procedures
Required Under the Sarbanes-Oxley Act of 2002

Within 90 days prior to the date of this quarterly report on Form 10-Q for the
third quarter ended September 30, 2002, the Company's President , acting as its
principal executive officer and principal financial officer, carried out an
evaluation of the effectiveness of the design and operation of the Company's
disclosure controls and procedures pursuant to Rule 13a-14 of the Securities
Exchange Act of 1934. Based upon that evaluation, the President concluded that
the Company's disclosure controls and procedures are effective in timely
alerting him to material information relating to the Company required to be
included in the Company's periodic SEC filings. There were no significant
changes in internal controls or in other factors that could significantly affect
internal controls subsequent to the date of the President's most recent
evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.


                                       10
<PAGE>

Item 6.  Exhibits and Reports on Form 8-K

         a)  Exhibits

             99.1       Statement Pursuant to Section 302 of the Sarbanes-Oxley
                        Act of 2002 By Principal Executive Officer Regarding
                        Facts and Circumstances Relating to Exchange Act Filings

         b)  The Company did not file any current reports on Form 8-K during the
             quarter ended September 30, 2002.




                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.


Dated:  November 13, 2002

                                   BIO-MEDICAL AUTOMATION, INC.


                                   By: /s/ Steven N. Bronson
                                       ------------------------------------
                                       Steven N. Bronson, President
                                       (Principle Executive Officer),
                                       as Registrant's duly authorized officer




                                       11